Motif Bio PLC Directorate Change (2921E)
05 May 2017 - 4:01PM
UK Regulatory
TIDMMTFB
RNS Number : 2921E
Motif Bio PLC
05 May 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
Motif Bio plc
("Motif Bio" or the "Company")
Motif Bio Announces Appointment of Dr. Craig Albanese as
Non-Executive Director
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces the
appointment of Dr. Craig T. Albanese to the Company's Board as
Non-Executive Director with immediate effect.
Dr. Albanese has 25 years of clinical and administrative
experience focusing on children and women's health, primarily in
the Stanford Children's Hospital, New-York Presbyterian Hospital,
Morgan Stanley Children's Hospital and the Sloane Hospital for
Women. He has had a distinguished clinical career to date having
published 161 peer review articles, contributed 57 book chapters,
and risen to Professor of Surgery in Paediatrics, Obstetrics and
Gynecology. He has combined his clinical career with success in
hospital administrative positions where he has had a pivotal role
in setting up networks of physicians, support, and educational
services across a number of hospitals and medical institutions to
provide integrated clinical and support services for increasing
numbers of patients in a very cost-effective way.
Richard Morgan, Chairman of Motif Bio, commented: "I am
delighted to welcome Craig to the Board of Motif Bio. We have seen
great progress in the development of iclaprim, our lead antibiotic
for serious Gram-positive infections, and with the publication of
the successful completion of the first Phase III clinical trial,
the Board is now increasingly focused on the commercialisation of
iclaprim in the US. Craig's experience and knowledge of both the
clinical reality and operational activities of large hospital
groups will prove invaluable in refining our commercialisation
strategy for iclaprim. We look forward to his input to the
team."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
- Full name and age: Craig Thomas Albanese (aged 55)
Dr. Albanese has been granted options to acquire 100,000
ordinary shares of 1p each in the Company at a price of 33.75p. The
options granted have a vesting period of 48 months, may be
exercised up to the tenth anniversary of the grant and are not
subject to performance criteria.
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
AIM Rules for Companies.
For further information please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief
Executive Officer)
Peel Hunt LLP (NOMAD
& BROKER)
Dr. Christopher Golden/
Oliver Jackson +44 (0)20 7418 8900
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio plc www.motifbio.com
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP),
infections often caused by MRSA (methicillin resistant
Staphylococcus aureus). Having completed the REVIVE-1 trial,
patients are currently being enrolled and dosed in a second global
Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2
is expected in the second half of 2017.
Notification and public disclosure of transactions by persons
discharging
managerial responsibilities and persons closely associated with
them
1. Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------------
a. Name Craig Thomas Albanese
--- ------------------------------ -------------------------------------
2. Reason for the notification
--- ---------------------------------------------------------------------
a. Position/status Non-Executive Director
--- ------------------------------ -------------------------------------
b. Initial notification Initial
/Amendment
--- ------------------------------ -------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------------
a. Name Motif Bio plc
--- ------------------------------ -------------------------------------
b. LEI 54930080DN00QTIUUU84
--- ------------------------------ -------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------------
a. Description Grant of options over ordinary
of the shares of 1p each in Motif Bio
Financial plc
instrument,
type
of instrument
Identification
code
--- ------------------------------ -------------------------------------
b. Nature of
the transaction Grant of options to acquire shares
--- ------------------------------ -------------------------------------
c. Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
33.75p 100,000
--------- ----------
--- ------------------------------ -------------------------------------
d. Aggregated
information
* Aggregated volume N/A
* Price
--- ------------------------------ -------------------------------------
e. Date of the 2017-05-05;
transaction
--- ------------------------------ -------------------------------------
f. Place of Outside a trading venue
the transaction
--- ------------------------------ -------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUVOVRBVAVRRR
(END) Dow Jones Newswires
May 05, 2017 02:01 ET (06:01 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024